Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9366396rdf:typepubmed:Citationlld:pubmed
pubmed-article:9366396lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C0041485lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C0135575lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C1138422lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C1416496lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:9366396lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:9366396pubmed:issue10lld:pubmed
pubmed-article:9366396pubmed:dateCreated1997-11-25lld:pubmed
pubmed-article:9366396pubmed:abstractTextRecent evidence indicates that integrin ligation results in activation of focal adhesion kinase (pp125FAK), the prototype of a new subfamily of nonreceptor protein tyrosine kinase (PTK), including FAKB and the proline-rich tyrosine kinase 2 (PYK-2), also termed cell adhesion kinase-beta or related adhesion focal tyrosine kinase. We have previously shown that cross-linking of alpha 4 beta 1 and alpha 5 beta 1 fibronectin receptors on human NK cells stimulates tyrosine phosphorylation of two proteins migrating at 105 and 115 kDa. Here we report that cross-linking of beta 1 integrins on human NK cells stimulates tyrosine phosphorylation and PTK activity of PYK-2. PYK-2 tyrosine phosphorylation was maximal at 1 min and started to decline 20 min after stimulation. Engagement of alpha 4 beta 1 and alpha 5 beta 1 either with specific mAbs or after cell adhesion to fibronectin or its 120- and 40-kDa fragments also triggered PYK-2 tyrosine phosphorylation. Stimulation of PYK-2 tyrosine phosphorylation was inhibited by the tyrosine kinase inhibitor herbimycin A, but not by EGTA, indicating that PYK-2 tyrosine phosphorylation is PTK, but not calcium, dependent. We also demonstrate that PYK-2 is constitutively associated with paxillin, which undergoes tyrosine phosphorylation with the same kinetics of PYK-2 upon beta 1 integrin ligation.lld:pubmed
pubmed-article:9366396pubmed:languageenglld:pubmed
pubmed-article:9366396pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9366396pubmed:statusMEDLINElld:pubmed
pubmed-article:9366396pubmed:monthNovlld:pubmed
pubmed-article:9366396pubmed:issn0022-1767lld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:PalmieriGGlld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:PiccoliMMlld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:SantoniAAlld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:FratiLLlld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:GismondiAAlld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:MainieroFFlld:pubmed
pubmed-article:9366396pubmed:authorpubmed-author:BisognoLLlld:pubmed
pubmed-article:9366396pubmed:issnTypePrintlld:pubmed
pubmed-article:9366396pubmed:day15lld:pubmed
pubmed-article:9366396pubmed:volume159lld:pubmed
pubmed-article:9366396pubmed:ownerNLMlld:pubmed
pubmed-article:9366396pubmed:authorsCompleteYlld:pubmed
pubmed-article:9366396pubmed:pagination4729-36lld:pubmed
pubmed-article:9366396pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:meshHeadingpubmed-meshheading:9366396-...lld:pubmed
pubmed-article:9366396pubmed:year1997lld:pubmed
pubmed-article:9366396pubmed:articleTitleProline-rich tyrosine kinase-2 activation by beta 1 integrin fibronectin receptor cross-linking and association with paxillin in human natural killer cells.lld:pubmed
pubmed-article:9366396pubmed:affiliationDepartment of Experimental Medicine and Pathology, University of Rome La Sapienza, Italy.lld:pubmed
pubmed-article:9366396pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9366396pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:9366396pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9366396lld:pubmed